Valion Bio, Inc. Amortization of Debt Discount (Premium)
Valion Bio, Inc. (VBIO) reported Amortization of Debt Discount (Premium) of $1.75 million for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-31.
Discontinued › Cash Flow › Operating Activities
us-gaap:AmortizationOfDebtDiscountPremium · last filed 2023-03-31
- Valion Bio, Inc. amortization of debt discount (premium) for the quarter ending 2021-12-31 was $134.00K.
- Valion Bio, Inc. amortization of debt discount (premium) for the quarter ending 2021-09-30 was $1.14M.
- Valion Bio, Inc. amortization of debt discount (premium) for the quarter ending 2021-06-30 was $208.00K.
- Valion Bio, Inc. amortization of debt discount (premium) for the quarter ending 2021-03-31 was $261.00K.
- Valion Bio, Inc. amortization of debt discount (premium) for fiscal 2021 was $1.75M.
| Period end | Amortization of Debt Discount (Premium) 3 month | Amortization of Debt Discount (Premium) 6 month | Amortization of Debt Discount (Premium) 9 month | Amortization of Debt Discount (Premium) 12 month |
|---|---|---|---|---|
| 2021-12-31 | $134.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $1.28M derived: sum of 2 quarters · filed 2023-03-31 | $1.49M derived: sum of 3 quarters · filed 2023-03-31 | $1.75M 10-K · filed 2023-03-31 |
| 2021-09-30 | $1.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $1.35M derived: sum of 2 quarters · filed 2022-11-14 | $1.61M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $208.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $469.00K 10-Q · filed 2022-08-15 | ||
| 2021-03-31 | $261.00K 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |